» Articles » PMID: 35676833

Oral Microbiota, a Potential Determinant for the Treatment Efficacy of Gastric Eradication in Humans

Overview
Journal Pol J Microbiol
Specialty Microbiology
Date 2022 Jun 9
PMID 35676833
Authors
Affiliations
Soon will be listed here.
Abstract

The oral cavity serves as another reservoir for gastric and may contribute to the failure of gastric eradication therapy. However, changes to the oral microbial composition after gastric eradication therapy has not yet been identified. This study aims to dissect whether the oral microbiota is involved and which bacterium mediates the clinic failure in eradication. In the present study, the oral microorganisms from patients who had received the gastric eradication treatment were analyzed by a high-throughput 16S rRNA deep sequencing. We found that the β diversity and composition of oral microbiota were remarkably changed in the patients who had experienced successful gastric eradication treatment (SE group) compared to the failure group (FE group). Significantly enriched families, including , , Caulobacteraceae, and Lactobacillaceae, were detected in the SE group. In contrast, the bacterial families, such as Weeksellaceae, Neisseriaceae, Peptostreptococcaceae, Spirochaetaceae, and Veillonellaceae, were abundantly expressed in the FE group. Five operational taxonomic units (OTUs) were positively correlated with DOB values, while two OTUs exhibited negative trends. These different enriched OTUs were extensively involved in the 20 metabolic pathways. These results suggest that a balanced environment in the oral microbiota contributes to eradication and metabolic homeostasis in humans. Our data demonstrated that the changes in oral microbiota might contribute to the therapeutic effects of antibiotic therapy. Therefore, a different therapy on the detrimental oral microbiota will increase the therapeutic efficacy of antibiotics on infection.

Citing Articles

Polymicrobial interactions of and its role in the process of oral diseases.

Fan Y, Chen X, Shan T, Wang N, Han Q, Ren B J Oral Microbiol. 2025; 17(1):2469896.

PMID: 40013013 PMC: 11864007. DOI: 10.1080/20002297.2025.2469896.


Helicobacter pylori in oral cavity: current knowledge.

Costa L, Carvalho M, Vale F, Marques A, Rasmussen L, Chen T Clin Exp Med. 2024; 24(1):209.

PMID: 39230790 PMC: 11374826. DOI: 10.1007/s10238-024-01474-1.


Novel MAXPOWER biological antibacterial liquid for eradicating oral Helicobacter pylori.

Lai Y, Dong X, Song Y, Zhao J, Du Y, Li Z BMC Infect Dis. 2024; 24(1):540.

PMID: 38811871 PMC: 11137934. DOI: 10.1186/s12879-024-09424-8.


Oral Microbiota and Tumor-A New Perspective of Tumor Pathogenesis.

Li S, He M, Lei Y, Liu Y, Li X, Xiang X Microorganisms. 2022; 10(11).

PMID: 36363799 PMC: 9692822. DOI: 10.3390/microorganisms10112206.

References
1.
Maruyama N, Maruyama F, Takeuchi Y, Aikawa C, Izumi Y, Nakagawa I . Intraindividual variation in core microbiota in peri-implantitis and periodontitis. Sci Rep. 2014; 4:6602. PMC: 4194447. DOI: 10.1038/srep06602. View

2.
Costalonga M, Herzberg M . The oral microbiome and the immunobiology of periodontal disease and caries. Immunol Lett. 2014; 162(2 Pt A):22-38. PMC: 4346134. DOI: 10.1016/j.imlet.2014.08.017. View

3.
Tohidpour A . CagA-mediated pathogenesis of Helicobacter pylori. Microb Pathog. 2016; 93:44-55. DOI: 10.1016/j.micpath.2016.01.005. View

4.
Yee J . Helicobacter pylori colonization of the oral cavity: A milestone discovery. World J Gastroenterol. 2016; 22(2):641-8. PMC: 4716065. DOI: 10.3748/wjg.v22.i2.641. View

5.
Chamanrokh P, Shahhosseiny M, Mazaheri Assadi M, Nejadsattari T, Esmaili D . Three Tests Used to Identify Non-Culturable Form of Helicobacter pylori in Water Samples. Jundishapur J Microbiol. 2015; 8(4):e16811. PMC: 4449853. DOI: 10.5812/jjm.8(4)2015.16811. View